Drug Trial Radar · NCT07155499
A Clinical Trial for Evaluation of Efficacy, Safety and Immunogenicity of GNR-127 (Recombinant ABP Antigen Protein Which Carries a Birch Pollen Allergen [BET V 1] and an Apple Allergen [MAL D 1]) in Patients With Birch Pollen Allergic Rhinitis.
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
150
Actual
Start
Oct 7, 2024
Primary completion
May 31, 2025
Study completion Sep 8, 2025
Sponsor
- Lead sponsor
- AO GENERIUMIndustry
- Sponsor type
- Industry
- First posted
- Sep 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is first-in-human phase 1/2 clinical trial to evaluate the safety, systemic and local reactogenicity of GNR-127 at the first stage in sequential cohorts of patients with allergic rhinitis with sensitization to the birch pollen, and then to determine and evaluate an effective and safe dose of the GNR-127 after five monthly administrations compared to placebo at the second stage.
Conditions
- Rhinitis, Allergic, Seasonal
Interventions
GNR-127, 20 mcgBiological
GNR-127, 20 mcg in 0.5 ml administered 5 times every 4 weeks
GNR-127, 40 mcgBiological
GNR-127, 40 mcg in 0.5 ml administered 5 times every 4 weeks
GNR-127, 80 mcgBiological
GNR-127, 80 mcg in 0.5 ml administered 5 times every 4 weeks
GNR-127 placeboBiological
GNR-127 placebo 0.5 ml administered 5 times every 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Daily Symptom Score (dSS)Time frame: Up to 3 months after the end of treatment.
- Daily Medication Score (dMS)Time frame: Up to 3 months after the end of treatment.
- Combined Symptom and Medication Score (CSMS)Time frame: Up to 3 months after the end of treatment.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Research Center - Institute of Immunology Federal Medical-Biological Agency
Moscow, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.